Romidepsin
- Generic Name
- Romidepsin
- Brand Names
- Istodax
- Drug Type
- Small Molecule
- Chemical Formula
- C24H36N4O6S2
- CAS Number
- 128517-07-7
- Unique Ingredient Identifier
- CX3T89XQBK
- Background
Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
- Indication
用于在已接受至少1次既往全身治疗的患者中皮肤T-细胞淋巴瘤的治疗(CTCL)。
- Associated Conditions
- Cutaneous T-Cell Lymphoma (CTCL)
- Associated Therapies
- -
Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas
- Conditions
- Refractory Mature T-Cell and NK-Cell Non-Hodgkin LymphomaT-Cell Non-Hodgkin LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Primary Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Mature T-Cell and NK-Cell Non-Hodgkin LymphomaRefractory Anaplastic Large Cell LymphomaRefractory Transformed Mycosis FungoidesRecurrent Transformed Mycosis FungoidesRecurrent Anaplastic Large Cell Lymphoma
- Interventions
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Walter Hanel
- Target Recruit Count
- 5
- Registration Number
- NCT04774068
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
- Conditions
- Interventions
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 50
- Registration Number
- NCT04747236
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸University of Virginia, Charlottesville, Virginia, United States
Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT04639843
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT04447027
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- GWT-TUD GmbH
- Target Recruit Count
- 75
- Registration Number
- NCT04257448
- Locations
- 🇩🇪
Universitätsklinikum Essen, Essen, Germany
🇩🇪Universitätsmedizin Göttingen, Göttingen, Germany
🇩🇪Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- Columbia University
- Registration Number
- NCT04233697
Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Rhizen Pharmaceuticals SA
- Target Recruit Count
- 33
- Registration Number
- NCT03770000
- Locations
- 🇺🇸
John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Rush University Cancer Center, Chicago, Illinois, United States
ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Celgene
- Target Recruit Count
- 150
- Registration Number
- NCT03742921
- Locations
- 🇯🇵
Nihon Seimei Hospital, Osaka, Japan
Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-10-12
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 93
- Registration Number
- NCT03703375
- Locations
- 🇯🇵
Local Institution - 41422, Hidaka, Saitama-Pref, Japan
🇯🇵Local Institution - 41222, Sendai, Japan
🇯🇵Local Institution - 41722, Osakasayama, Osaka, Japan
Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL
- Conditions
- Interventions
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 86
- Registration Number
- NCT03593018
- Locations
- 🇧🇪
CHU UCL Namur - Site Godinne, Yvoir, Belgium
🇦🇹Medical University of Vienna, Vienna, Austria
🇧🇪A. Z. Sint-Jan Brugge-Oostende AV, Bruges, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.